Articles On Neuren Pharmaceuticals (ASX:NEU)

It was a positive end to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Friday. A third day of gains in a row for the ASX 200 saw it close at 8,231.2 points today. T...

Highlights: ANZ Group provides insights into first-half earnings, with a focus on capital stability and strategic de-risking. S&P/ASX 200 remains flat at noon with fluctuations across various sectors. Unusual volume obse...

Highlights Neuren Pharmaceuticals (NEU) reported strong sales figures in the biotech sector. Pointerra (3DP) advanced in the tech space with a US Army contract. Locksley Resources (LKY) moved forward with drilling approvals...

The ASX200 has been up 0.2% at around 8,195 points. Neuren Pharmaceuticals (ASX:NEU) has been the most watched on HotCopper so far today, after reporting Q1 FY25 sales of its DAYBUE product increased by 11% to US$84.6 million over the co...

Neuren says the number of patients discontinuing its Rett syndrome drug has fallen by two-thirds over the last year LTR Pharma launches a secondary program for swallowing disorders Telix targets throat – and other – cancers Neuren Pharmac...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13...

Highlights Several ASX 200 directors made notable share purchases, including from Neuren Pharmaceuticals, BHP, GQG Partners, and Viva Energy Group. BHP's directors acquired additional shares amid market fluctuations, while GQG's...

Highlights Australian sharemarket closes higher following positive global trade sentiment Technology sector leads with strong gains, while Neuren Pharmaceuticals and DroneShield advance Broad-based gains seen across sectors,...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ASX200 futures are pointing to a positive start, up 18 points, but US markets finish...

Neuren Pharmaceuticals (ASX:NEU) and its US partner Acadia Pharmaceuticals have been blitzing it with its Rett syndrome drug Daybue (formerly trofinetide), which has exceeded the expectations of two years ago when the drug was approved in t...

Highlights: Australian sharemarket finished higher, supported by broader strength across Asian equities and US futures Technology sector led the gains, advancing the most among all sectors Neuren Pharmaceuticals and DroneShi...

Highlights Technology and materials sectors led the ASX gains amid stronger iron ore and gold prices Elixir Energy lifted as leadership transitioned to former Strike Energy executive EBR Systems declined following FDA approv...

Highlights: The ASX 200 Index closed higher as most sectors ended the session in positive territory. Tech, materials, and healthcare shares were among the top-performing sectors. Neuren Pharmaceuticals topped the leaderboard...

It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By th...

ASX climbs 1.34pc with 10/11 sectors in the green Base metal prices recover as USD falls Gold continues strong performance, remaining near all-time highs   It’s certainly a calmer start to the week for the markets today. Strong numbers fr...

Good Afternoon and welcome to HotCopper’s Market Close for Monday 14th of April, I’m Jonathon Davidson. The local bourse traded green on Monday with IT in the lead up 2.6% led by Wall Street, followed by Materials up 2.1%, led by higher...

Highlights Mining and banking sectors lifted the ASX, with broad market strength across major indices Technology and real estate stocks added further support amid easing trade tensions Neuren Pharmaceuticals surged after pos...

Highlights Mining, financials, and energy sectors lead upward momentum Major banks and resource companies post solid intraday advances DroneShield and Neuren Pharmaceuticals record strong intraday surges The Australian...

Highlights: ASX rises strongly during midday trade amid easing trade tensions between the US and China Neuren Pharmaceuticals jumps after Phase 3 trial confirmation for rare neurological condition Grand Gulf Energy leads sma...

Highlights Miners and banks fuel broad ASX gains Tech and gold stocks shine on global cues Neuren Pharmaceuticals soars after FDA milestone The Australian sharemarket kicked off the week on a strong note, with major gains led by m...

Highlights  ASX rises on global tech optimism and commodity gains  Neuren Pharmaceuticals leads with double-digit surge  Strong moves seen in tech, mining, and defense sectors  Australian shares climbed on Monday as optimism aroun...

Neuren Pharma (ASX:NEU) has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome (PMS) – the first ever to be conducted. Listen to the HotCopper podcast for in-depth discussions and insi...

The ASX has been up 1% higher at 7,721 points. Invictus Energy (ASX:IVZ) has been among the most watched on HotCopper forums after the company confirmed Musuma-1 as the first high-impact exploration well to be drilled outside the Mukuyu...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points. Four ASX shares that are rising more than most today are listed below. He...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week with an almighty bang. In morning trade, the ASX 200 biotech stock is up a massive 18% to $10.83. Why is this ASX 200 stock jumping? Investors have been bidding the pharmace...

Highlights Major U.S. indexes, including the S&P 500 and Nasdaq, experience significant overnight gains. Australian pharmaceutical stocks fluctuate after recent tariff updates. Investors watch closely for companies that don’t foll...

The US market took off, in a fashion I’ve not seen in my career, after Trump sent this message on his social media platform: “Authorised a 90 day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effectiv...

Highlights: Short interest surged across uranium developers and producers amid sector-wide declines. James Hardie recorded a sharp uptick in short interest after a controversial acquisition. Limited short covering observed,...

Highlights: Neuren Pharmaceuticals reports a price-to-earnings ratio below the broader market. The company's earnings have shown a decline, influencing its valuation. Market expectations indicate continued financial challeng...

Highlights: ASX 200 moves higher with technology and real estate stocks gaining traction. Light & Wonder and Megaport stand out with notable price increases. Some resource stocks experience declines, including Liontown a...

Some investors contend Clinuvel’s mountain of $200 million of cash is excessive and amounts to a ‘lazy’ balance sheet The company argues the cash buffer protects it against unexpected adversities and – in any event – every cent will be nee...

Highlights: ASX200 sees fluctuations as various sectors experience gains and declines. Energy and Consumer Staples lead with positive performances, while Information Technology faces setbacks. Notable stock movements inclu...

The ASX200 closed down 0.38% at 7,969 points. Energy was the best performing sector, up1%, followed by Staples, up 0.4%, and Materials, up 0.33%. Real Estate was the biggest loser, down 2.2%, followed, IT, down 2%, and Discretionary,...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and dropping into the red. At the time of writing, the benchmark index is down 0.6% to 7,953.4 points. Four ASX shares that are not letting that hold them back are lis...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

A couple of ASX 200 biotech stocks are in the spotlight today after releasing big news. However, while one is pushing higher, the other has dropped into the red. Let's see what is happening: Mesoblast Ltd (ASX: MSB) The Mesoblast share pri...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a pleasant end to the trading week this Friday, clawing back some of the week's lost ground to finish in the green. By the time the closing bell rang, t...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff. The ASX 200 stock ended the day 6% lower at $11.40. This leaves the pharmaceutical company's shares trading within sight...

The Australian share market is a sea of red again on Tuesday. Investors have been hitting the sell button in a panic following a selloff on Wall Street caused by US recession concerns. While the market volatility can be hard to stomach, his...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

ASX investors finally caught another break this Thursday, with the S&P/ASX 200 Index (ASX: XJO) rising for only its second session in the past nine trading days. By the time the markets closed...

Highlights: Karoon Energy strengthens its operational framework with an asset acquisition for its Brazil-based project. Qantas announces a dividend reinstatement, reflecting financial recovery in the aviation sector. Fluctuations...

Good afternoon and welcome to the Thursday edition of Market Close, I’m Jonathon Davidson. It was a somewhat happier day as Australian icon Qantas paid its first dividend in years and household name Coles proved to be consistently growing....

The S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain on Thursday. In afternoon trade, the benchmark index is up 0.4% to 8,272 points. Four ASX shares that are rising more than most today are listed below. Here's why the...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day...